Premium
Anidulafungin Does Not Require Dosage Adjustment in Subjects With Varying Degrees of Hepatic or Renal Impairment
Author(s) -
Dowell James A.,
Stogniew Martin,
Krause David,
Damle Bharat
Publication year - 2007
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270006297227
Subject(s) - anidulafungin , medicine , pharmacology , dosage form , antifungal , micafungin , amphotericin b , dermatology
Two open‐label studies assessed the effects of hepatic and renal impairment on anidulafungin pharmacokinetics. A single 50‐mg dose was administered intravenously to subjects with varying degrees of hepatic or renal insufficiency or with end‐stage renal disease; all were matched to normal healthy controls. Anidulafungin was well tolerated. AUC, CL, C max , t max , t 1/2 , and V ss between renally impaired subjects and controls were not significantly different ( P .05), and no measurable amounts of drug were found in dialysate. The same pharmacokinetic parameters were also not affected ( P .05) by mild or moderate hepatic insufficiency, with respective mean AUCs of 50.6 ± 11.7 μg·h/mL and 68.6 ± 14.5 μg·h/mL, compared to 70.0 ± 13.4 μg·h/mL in controls. Statistically significant decreases ( P < 05) of AUC (33% change) and C max (36% change) in severely hepatically impaired subjects compared to controls—most likely secondary to ascites and edema—were not clinically relevant. Anidulafungin can be safely administered to patients with any degree of hepatic or renal impairment without dosage adjustment and without regard to hemodialysis schedules.